41 results on '"Hertweck, Maren"'
Search Results
2. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
3. Safety and efficacy of tafasitamab ± lenalidomide added to first-line R‑CHOP for DLBCL: Phase 1b First-MIND study
4. Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor
5. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
6. A phase 2a, single‐arm, open‐label study of tafasitamab, a humanized, Fc‐modified, anti‐CD19 antibody, in patients with relapsed/refractory B‐precursor cell acute lymphoblastic leukemia
7. Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
8. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
9. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
10. Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
11. Recent aging research in Caenorhabditis elegans
12. ABCL-170: Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
13. A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis
14. Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)
15. Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
16. C. elegans, a model for aging with high-throughput capacity
17. Inhibition of nuclear pre-mRNA splicing by antibiotics in vitro
18. Mapping divalent metal ion binding sites in a group II intron by Mn2+- and Zn2+-induced site-specific RNA cleavage
19. Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis.
20. Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind
21. Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy
22. SHC-1/p52Shc targets the insulin/IGF-1 and JNK signaling pathways to modulate life span and stress response in C. elegans
23. Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study
24. Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis
25. Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans
26. A Novel Sorting Nexin Modulates Endocytic Trafficking and α-Secretase Cleavage of the Amyloid Precursor Protein
27. Direct Inhibition of the Longevity-Promoting Factor SKN-1 by Insulin-like Signaling in C. elegans
28. Endocrine signaling in Caenorhabditis elegans controls stress response and longevity
29. Automated assays to study longevity in C. elegans
30. (Dipeptide) nutrition, ageing, and C. elegans
31. C. elegans SGK-1 Is the Critical Component in the Akt/PKB Kinase Complex to Control Stress Response and Life Span
32. Inhibition of nuclear pre-mRNA splicing by antibioticsin vitro
33. Mapping divalent metal ion binding sites in a group II intron by Mn2+- and Zn2+-induced site-specific RNA cleavage.
34. Endocrine signaling in Caenorhabditis eleganscontrols stress response and longevity
35. Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind
36. A Novel Sorting Nexin Modulates Endocytic Trafficking and α-Secretase Cleavage of the Amyloid Precursor Protein.
37. Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.
38. A novel sorting nexin modulates endocytic trafficking and alpha-secretase cleavage of the amyloid precursor protein.
39. Aging at the interface of stem cell renewal, apoptosis, senescence, and cancer.
40. C. elegans gives the dirt on aging.
41. Genes, longevity, and technology: meeting report from the 2nd conference on functional genomics of aging in Crete.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.